NCT05989425招募中2 期
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer: an Open-label, Multicenter, Single-arm Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer. Therefore, more effective treatments are urgently needed. This study is designed to evaluate the efficacy and safety of the Surufatinib for Locally Advanced Thyroid Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Locally advanced or metastatic thyroid cancer confirmed by histology or cytology, including papillary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated thyroid cancer, particularly differentiated thyroid cancer. Locally advanced stage refers to: 1) Primary tumor with invasion or adhesion of organs and structures, such as recurrent laryngeal nerve, esophagus, trachea, larynx, encirclement of neck large vessels, mediastinal vessels, extensive invasion of skin, subcutaneous soft tissue or neck muscles; 2). AJCC T4 Stage; 3). Difficult to achieve R0/R1 resection during preoperative assessment;
- •Age 14-75 years;
- •At least one measurable lesion (RECIST 1.1);
- •Eastern Cooperative Oncology Group (ECOG) score 0-1;
- •Expected survival time ≥ 12 weeks;
- •The main organ functions meet the following criteria: Absolute neutrophil value (ANC) ≥ 1.5 × 109 / L; Platelet (PLT) ≥80 × 109 / L; Hemoglobin (HB) ≥9g / dL; White blood cell count> 1.5 × 109 / L; Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN, if with liver metastases, ALT and AST ≤ 5 ULN; Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr) ≥ 50ml / min;
- •Subjects of potential fertility are required to use at least one medically approved contraceptive method (such as an intrauterine device, contraceptive pill, or condom) during the study treatment and for 180 days after the end of the study treatment; The serum HCG test must be negative before the first medication.
排除标准
- •Prior treatment with anti-angiogenic small molecule targeted drugs;
- •Received other anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, etc.) within 4 weeks prior to treatment, except for TSH suppression treatment;
- •Allergy to the study drug ;
- •Have a history of serious cardiovascular and cerebrovascular diseases;
- •Patients whose imaging showed that the tumor had invaded the important blood vessels or the researchers judged that the tumor was likely to invade important blood vessels during the subsequent study period and caused fatal bleeding;
- •Patients with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg);
- •The patient has had other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- •The investigator considered that the subject was not suitable to participate in the study due to any clinical or laboratory abnormalities or other reasons.
研究组 & 干预措施
surufatinib
Experimental
Surufatinib 300mg will be taken orally once daily continuously through a 28-day cycle of study treatment. After treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination. Patients with high risk of postoperative recurrence will receive 131I treatment. After 131I treatment, maintenance treatment with surufatinib will be determined according to the recurrence risk stratification.
干预措施: surufatinib (Drug)
结局指标
主要结局
ORR
时间窗: approximately 1 years
Objective Response Rate
次要结局
- R0/1 resection rate(approximately 1 years)
- DCR(approximately 1 years)
- PFS(approximately 1 years)
- AE(From first dose to within 30 days after the last dose)
研究者
Chen Jiaying
Professor, Fudan University Shanghai Cancer
Fudan University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland CarcinomasSalivary Gland CarcinomasNCT05013515Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University20
Unknown
2 期
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid CancerThyroid CancerNCT04309136Fudan University13
已完成
2 期
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid CancerThyroid Cancer, AnaplasticNCT03565536Fujian Medical University18
终止
2 期
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid CarcinomaThyroid CancerNCT00115739University of Michigan Rogel Cancer Center11
招募中
2 期
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)Anaplastic Thyroid CancerNCT06079333Leiden University Medical Center20